Printer Friendly

Qualcomm, Boehringer Ingelheim Pharmaceuticals Work to Add New Digital Technology to Respimat inhaler.

M2 PHARMA-August 31, 2016-Qualcomm, Boehringer Ingelheim Pharmaceuticals Work to Add New Digital Technology to Respimat inhaler

(C)2016 M2 COMMUNICATIONS

- German pharmaceutical company Boehringer Ingelheim's US unit and US-based technology company Qualcomm Inc.'s (NASDAQ: QCOM) Qualcomm Life, Inc subsidiary will collaborate to develop a connectivity solution for the Respimat inhaler, the platform inhaler for the Boehringer Ingelheim family of respiratory therapies, to help improve COPD treatment outcomes, the companies said.

Through its 2net Design platform, Qualcomm Life is developing the prototype for a small, wireless, low-power, disposable module for the Respimat inhaler.

This fully-integrated inhaler, which is designed to seamlessly connect with Qualcomm Life's 2net Platform, will be able to track puffs from the Respimat inhaler, and the collected information can be shared with health care providers and people who have been prescribed one of Boehringer Ingelheim's Respimat medicines.

As with other chronic diseases, poor adherence to treatment plans is common among people with COPD and can result in increased rates of COPD symptoms, health care costs, hospitalizations and even death.

The collaboration seeks to combine Boehringer Ingelheim's leadership in discovering and developing COPD medicines with Qualcomm Life's expertise in developing reference designs for wireless, single-use and small integrated modules to create a solution to support adherence to daily treatment regimens.

Leveraging Qualcomm Life's deep wireless expertise and technologies, 2net Design is a platform for designing the communications components of connected medical devices, including disposable drug delivery devices and disposable diagnostic devices for condition specific connected therapies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 31, 2016
Words:259
Previous Article:Bluegrass Vascular Secures CE Mark Approval for Surfacer Inside-Out Access Catheter System.
Next Article:Bio2 Medical Raises USD 3m from Venture Debt Financing.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters